Literature DB >> 15467912

Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro.

Stephanie L Osip1, Martin Butcher, Edward Young, Lufang Yang, Stephen G Shaughnessy.   

Abstract

We have previously demonstrated that heparin produces cancellous bone loss in rats due in part to a decrease in the number of osteoblasts lining the trabecular bone surface. In the present study, we use a stromal-derived cell culture system together with measurements of alkaline phosphatase (ALP) activity, to compare the effects of heparin and the low molecular weight heparin (LMWH), Fragmin, on osteoblast differentiation in vitro. In addition, we examined the possibility that both heparin and LMWH can induce adipogenesis in our stromal cell culture system. Both heparin and LMWH were found to produce a statistically significant (P < 0.01) and concentration-dependent decrease in the number of osteoblasts while increasing the number of adipocytes. When the effects of gravimetrically equivalent amounts of heparin and LMWH were compared, heparin had a 4-fold greater effect than LMWH. In contrast to heparin, N-desulfated heparin was found to have minimal effects on both osteoblast and adipocyte differentiation indicating that the heparin effect is not only chain-length dependent but also charge-dependent. The observation that LMWH has less of an effect on bone formation than heparin is compatible with the results of clinical trials indicating that LMWH produces less bone loss after long-term administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467912     DOI: 10.1160/TH04-03-0199

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation.

Authors:  Weijun Luo; Hailu Shitaye; Michael Friedman; Christina N Bennett; Joshua Miller; Ormond A Macdougald; Kurt D Hankenson
Journal:  Exp Cell Res       Date:  2008-07-12       Impact factor: 3.905

2.  The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing.

Authors:  Kambiz Sarahrudi; Georg Kaiser; Anita Thomas; Mark Michel; Harald Wolf; Mehdi Mousavi; Seyedhossein Aharinejad
Journal:  Int Orthop       Date:  2011-10-29       Impact factor: 3.075

3.  The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

Authors:  Gandhi N Solayar; Pauline M Walsh; Kevin J Mulhall
Journal:  BMC Musculoskelet Disord       Date:  2011-10-28       Impact factor: 2.362

4.  The Effect of Low Molecular Weight Heparins on Fracture Healing.

Authors:  Stylianos Kapetanakis; Evangelos Nastoulis; Theano Demesticha; Thespis Demetriou
Journal:  Open Orthop J       Date:  2015-06-26

5.  Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model.

Authors:  Peter Michael Prodinger; Rainer Burgkart; Kilian Kreutzer; Franz Liska; Hakan Pilge; Andreas Schmitt; Martina Knödler; Boris Michael Holzapfel; Alexander Hapfelmeier; Thomas Tischer; Oliver Bissinger
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

6.  Agent specific effects of anticoagulant induced alopecia.

Authors:  Angela C Weyand; Jordan A Shavit
Journal:  Res Pract Thromb Haemost       Date:  2017-05-30

Review 7.  Anticoagulants and Osteoporosis.

Authors:  Salvatore Santo Signorelli; Salvatore Scuto; Elisa Marino; Michele Giusti; Anastasia Xourafa; Agostino Gaudio
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

Review 8.  The Role of Mast Cells in Bone Metabolism and Bone Disorders.

Authors:  Deniz Ragipoglu; Anne Dudeck; Melanie Haffner-Luntzer; Martin Voss; Jochen Kroner; Anita Ignatius; Verena Fischer
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.